COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
17 hedge funds and large institutions have $998K invested in COSCIENS Biopharma Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 4 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
58% more capital invested
Capital invested by funds: $633K → $998K (+$365K)
0% more funds holding
Funds holding: 17 → 17 (0)
0% more ownership
Funds ownership: 0.05% → 0.05% (+0%)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
+$18.3K |
| 2 |
Jane Street
New York
|
+$14.8K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$3.84K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$824 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$641 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$26K |
| 2 |
Morgan Stanley
New York
|
-$18.7K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$366 |
CSCI Hedge Fund Activity: Q2 2020 in Review
17 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q2 2020, worth a combined $998K — up 58% from $633K a quarter earlier.
Fund positioning in CSCI was balanced in Q2 2020: 4 funds opened new positions, 4 closed out, 4 added to existing stakes and 1 trimmed.
The largest buyer was Wedbush Securities, opening a new position worth an estimated $18.3K. The largest seller was BlackRock, exiting entirely with an estimated $26K sold.
- 17 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q2 2020, unchanged from Q1 2020.
- Funds reported $998K of COSCIENS Biopharma Inc. Common Stock stock for Q2 2020, up 58% quarter-over-quarter.
- 4 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q2 2020 and 4 closed out, a net change of 0 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q2 2020 was Wedbush Securities, an estimated $18.3K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q2 2020 was BlackRock, an estimated $26K sold.
Based on aggregated 13F filings for Q2 2020.